Kentaro Hanami

Kitakyushu, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 40 publications

Real-world effectiveness, safety and patient-reported outcomes of sarilumab in patients with rheumatoid arthritis: a 52-week, prospective, open-label, non-interventional, observational, nationwide, large-cohort study in Japan (PROFILE-J).

Real-world effectiveness, safety and patient-reported outcomes of sarilumab in patients with rheumatoid arthritis: a 52-week, prospective, open-label, non-interventional, observational, nationwide, large-cohort study in Japan (PROFILE-J).

Journal: RMD open

Published: October 15, 2025

Biological/targeted synthetic DMARDs do not arrest bone loss in patients with rheumatoid arthritis: a long-term multicenter observational study.

Biological/targeted synthetic DMARDs do not arrest bone loss in patients with rheumatoid arthritis: a long-term multicenter observational study.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: October 06, 2025

A case of newly onset rheumatoid arthritis successfully treated with methotrexate under the antiretrovirus therapy against HIV infection.

A case of newly onset rheumatoid arthritis successfully treated with methotrexate under the antiretrovirus therapy against HIV infection.

Journal: Modern rheumatology case reports

Published: December 16, 2024

Switching to biological DMARDs versus cycling among JAK inhibitors in patients with rheumatoid arthritis and with inadequate response to JAK inhibitors: from FIRST registry.

Switching to biological DMARDs versus cycling among JAK inhibitors in patients with rheumatoid arthritis and with inadequate response to JAK inhibitors: from FIRST registry.

Journal: RMD open

Published: September 11, 2024

Peripheral blood immunophenotypic diversity in patients with rheumatoid arthritis and its impact on therapeutic responsiveness.

Peripheral blood immunophenotypic diversity in patients with rheumatoid arthritis and its impact on therapeutic responsiveness.

Journal: Annals of the rheumatic diseases

Published: June 06, 2024

Predictors of the effectiveness of first-line CTLA4-Ig in patients with RA: the FIRST registry.

Predictors of the effectiveness of first-line CTLA4-Ig in patients with RA: the FIRST registry.

Journal: Rheumatology (Oxford, England)

Published: April 10, 2024

Efficacy, safety and optimal intervention of belimumab for proliferative lupus nephritis patients in real-world settings: LOOPS registry.

Efficacy, safety and optimal intervention of belimumab for proliferative lupus nephritis patients in real-world settings: LOOPS registry.

Journal: Rheumatology (Oxford, England)

Published: April 02, 2024

A case of immunoglobulin G4-related disease complicated by atopic dermatitis responsive to upadacitinib treatment.

A case of immunoglobulin G4-related disease complicated by atopic dermatitis responsive to upadacitinib treatment.

Journal: Modern rheumatology case reports

Published: March 12, 2024

Comparison of anti-IL-6 receptor and JAK inhibitors in patients with rheumatoid arthritis from the real-world practice FIRST registry.

Comparison of anti-IL-6 receptor and JAK inhibitors in patients with rheumatoid arthritis from the real-world practice FIRST registry.

Journal: Rheumatology (Oxford, England)

Published: March 09, 2024

Generation-Dependent Retention Rates and Reasons for Discontinuation of Molecular Targeted Therapies in Patients with Rheumatoid Arthritis: From FIRST Registry.

Generation-Dependent Retention Rates and Reasons for Discontinuation of Molecular Targeted Therapies in Patients with Rheumatoid Arthritis: From FIRST Registry.

Journal: Rheumatology and therapy

Published: August 17, 2023

Safety and efficacy of anifrolumab therapy in systemic lupus erythematosus in real-world clinical practice: LOOPS registry.

Safety and efficacy of anifrolumab therapy in systemic lupus erythematosus in real-world clinical practice: LOOPS registry.

Journal: Rheumatology (Oxford, England)

Published: July 17, 2023

Biological/targeted synthetic DMARDs do not arrest bone loss in patients with rheumatoid arthritis: a multicenter prospective observational study.

Biological/targeted synthetic DMARDs do not arrest bone loss in patients with rheumatoid arthritis: a multicenter prospective observational study.

Journal: Rheumatology (Oxford, England)

Published: June 12, 2023

Showing 1-12 of 40

Last Updated: 09/26/2026